Prelude Therapeutics (PRLD) Consolidated Net Income (2019 - 2026)
Prelude Therapeutics (PRLD) reported Consolidated Net Income of -$34.4 million for Q1 2026, up 40.15% on a YoY basis from -$24.6 million in Q1 2025, and down 90.49% sequentially from -$18.1 million in Q4 2025.
Prelude Therapeutics (PRLD) Consolidated Net Income (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of Consolidated Net Income data on file, last reported at -$34.4 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income rose 40.15% year-over-year to -$34.4 million; the trailing twelve-month figure through Mar 2026 stood at -$149.0 million (up 39.97% YoY), and the FY2025 full-year result was -$316.5 million, up 1.83% from the prior year.
- Consolidated Net Income retreated to -$34.4 million in Q1 2026, from -$18.1 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$18.1 million in Q4 2025 to a low of -$144.4 million in Q4 2022.
- A 5-year average of -$52.4 million and a median of -$41.6 million in 2022 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income surged 83.64% in 2022 and slumped 112.54% in 2024, its largest moves.
- Tracing PRLD's Consolidated Net Income over 5 years: stood at -$144.4 million in 2022, then jumped by 73.79% to -$37.9 million in 2023, then grew by 9.24% to -$34.4 million in 2024, then surged by 47.38% to -$18.1 million in 2025, then plunged by 90.49% to -$34.4 million in 2026.
- Business Quant data shows PRLD's Consolidated Net Income at -$34.4 million in Q1 2026, -$18.1 million in Q4 2025, and -$42.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | -34.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.44 Mn |
| Dec 31, 2025 | -18.08 Mn |
| Sep 30, 2025 | -42.02 Mn |
| Jun 30, 2025 | -54.47 Mn |
| Mar 31, 2025 | -57.55 Mn |
| Dec 31, 2024 | -34.36 Mn |
| Sep 30, 2024 | -76.48 Mn |
| Jun 30, 2024 | -79.85 Mn |
| Mar 31, 2024 | -77.64 Mn |
| Dec 31, 2023 | -37.86 Mn |
| Sep 30, 2023 | -35.99 Mn |
| Jun 30, 2023 | -37.80 Mn |
| Mar 31, 2023 | -38.22 Mn |
| Dec 31, 2022 | -144.44 Mn |
| Sep 30, 2022 | -42.51 Mn |
| Jun 30, 2022 | -37.16 Mn |
| Mar 31, 2022 | -41.59 Mn |
| Dec 31, 2021 | -108.38 Mn |
| Sep 30, 2021 | -170.14 Mn |
| Jun 30, 2021 | -159.02 Mn |